MANILA, Philippines — Indian vaccine maker Bharat Biotech submitted the interim data from phase 3 trials of its COVID-19 jab to the Food and Drug Administration (FDA) on Tuesday evening, India’s ambassador to the Philippines disclosed Wednesday.
Ambassador Shambhu Kumaran also expressed eagerness to begin negotiations with the Philippine government for the supply of Bharat Biotech’s Covaxin.
India’s biotech firm applied for an emergency use authorization (EUA) of Covaxin in January. However, FDA Director-General Eric Domingo said in February that the company has yet to submit documents from clinical trials for its anti-coronavirus drug.
“I am not sure why we have not start…
Keep on reading: Covaxin phase 3 trial data now with FDA; envoy awaits start of negotiations for supply